Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

ViaCyte to Present at Three Upcoming Healthcare Events


SAN DIEGO, Jan. 19, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced participation in three upcoming healthcare events. ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes. The company's lead PEC-DirectTM product candidate is in clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.  The related PEC-EncapTM product candidate, and a candidate called PEC-QT based on the use of a gene edited immune-evasive cell line, are also in development and have the potential to provide a functional cure for essentially all patients with insulin-requiring diabetes, both type 1 and type 2.

ViaCyte logo. (PRNewsFoto/ViaCyte, Inc.)

Details of the events are as follows:

Event:

Phacilitate Cell & Gene Therapy World

Speaker:

Dr. Mark Zimmerman, Vice President, Strategy and Business Development

Title:

Case study: Developing a cell therapy combination product for diabetes

Date/Time:

January 24, 4:05 PM ET

Location:

Hyatt Regency, Miami, Florida



Event:

Arab Health Exhibition and Congress

Presenters:

Dr. Paul Laikind, President and CEO
Dr. Mark Zimmerman, Vice President, Strategy and Business Development

Date/Time:

January 29 to February 1

Location:

Johnson & Johnson Exhibit in the UAE Ministry of Health area; Dubai International Convention and Exhibition Centre, Dubai, United Arab Emirates



Event:

2018 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium

Speaker:

Dr. Evert Kroon, Senior Director, Research Physiology

Session:

Encapsulation and Mechanical Immunoprotective Approaches in Beta Cell Replacement

Title:

Macroencapsulation Approaches

Date/Time:

February 1, 8:45 AM PT

Location:

The Langham Huntington, Pasadena, California

For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices.  Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.  ViaCyte has two product candidates in clinical-stage development.  The PEC-Directtm product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes.  The PEC-Encaptm (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin.  ViaCyte is also developing immune-evasive 'universal donor' stem cell lines, from its proprietary CyT49 cell line, expected to further broaden the availability of cell therapy for diabetes and other indications.  ViaCyte is headquartered in San Diego, California.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.  For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook.

 

SOURCE ViaCyte, Inc.


These press releases may also interest you

at 00:30
Frost & Sullivan recently researched the data center colocation services industry and, based on its findings, recognizes STT GDC India with the 2023 Indian Company of the Year Award. STT GDC India is a pioneer data center solutions provider that...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

at 00:24
In the news release, Roborock Reports 2023 Full Year Financial Results, issued 28-Mar-2024 by Roborock over PR Newswire, we are advised by the company that in the first bullet point of "Growth across Product Categories", the USD amount should read...

28 mar 2024
The opening ceremony of the Boao Forum for Asia (BFA) Annual Conference 2024 was held in Boao, south China's Hainan Province on Thursday, with China's top legislator Zhao Leji stressing China's economic potential, appealing to international investors...

28 mar 2024
OKX Ventures, the investment arm of leading Web3 technology company OKX, has issued updates for March 29, 2024. OKX Ventures...

28 mar 2024
Curio Legacy Ventures (Curio), a frontrunner in nuclear technology innovation, proudly announces a strategic partnership with Navarro Research and Engineering, Inc. (Navarro). This collaboration signals a significant step forward in advancing nuclear...



News published on and distributed by: